Universidad Peruana Cayetano Heredia

Cost-effectiveness of norovirus vaccination in children in Peru

Mostrar el registro sencillo del ítem

dc.contributor.author Mirelman, Andrew J.
dc.contributor.author Ballard, Sarah Blythe
dc.contributor.author Saito, Mayuko
dc.contributor.author Kosek, Margaret N.
dc.contributor.author Gilman, Robert Hugh
dc.date.accessioned 2019-02-06T14:57:43Z
dc.date.available 2019-02-06T14:57:43Z
dc.date.issued 2015
dc.identifier.uri https://hdl.handle.net/20.500.12866/5501
dc.description.abstract BACKGROUND: With candidate norovirus (NV) vaccines in a rapid phase of development, assessment of the potential economic value of vaccine implementation will be necessary to aid health officials in vaccine implementation decisions. To date, no evaluations have been performed to evaluate the benefit of adopting NV vaccines for use in the childhood immunization programs of low- and middle-income countries. METHODS: We used a Markov decision model to evaluate the cost-effectiveness of adding a two-dose NV vaccine to Peru's routine childhood immunization schedule using two recent estimates of NV incidence, one for a peri-urban region and one for a jungle region of the country. RESULTS: Using the peri-urban NV incidence estimate, the annual cost of vaccination would be $13.0 million, offset by $2.6 million in treatment savings. Overall, this would result in 473 total DALYs averted; 526,245 diarrhea cases averted;153,735 outpatient visits averted; and 414 hospitalizations averted between birth and the fifth year of life. The incremental cost-effectiveness ratio would be $21,415 per DALY averted; $19.86 per diarrhea case; $68.23 per outpatient visit; and $26,298 per hospitalization. Using the higher jungle NV incidence rates provided a lower cost per DALY of $10,135. The incremental cost per DALY with per-urban NV incidence is greater than three times the 2012 GDP per capita of Peru but the estimate drops below this threshold using the incidence from the jungle setting. In addition to the impact of incidence, sensitivity analysis showed that vaccine price and efficacy play a strong role in determining the level of cost-effectiveness. CONCLUSIONS: The introduction of a NV vaccine would prevent many healthcare outcomes in the Peru and potentially be cost-effective in scenarios with high NV incidence. The vaccine cost-effectiveness model could also be applied to the evaluation of NV vaccine cost-effectiveness in other countries. In resource-poor settings, where NV incidence rates are expected to be higher. en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Vaccine
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Peru en_US
dc.subject Humans en_US
dc.subject Child, Preschool en_US
dc.subject Infant en_US
dc.subject Cohort Studies en_US
dc.subject Peru/epidemiology en_US
dc.subject Developing Countries en_US
dc.subject Diarrhea en_US
dc.subject LMIC en_US
dc.subject Immunization Programs en_US
dc.subject Norovirus en_US
dc.subject Vaccine en_US
dc.subject Cost-Benefit Analysis en_US
dc.subject Infant, Newborn en_US
dc.subject Cost-effectiveness en_US
dc.subject Caliciviridae Infections/economics/epidemiology/prevention & control en_US
dc.subject Caliciviruses en_US
dc.subject Gastroenteritis en_US
dc.subject Gastroenteritis/economics/epidemiology/prevention & control en_US
dc.subject Norovirus/immunology en_US
dc.subject Vaccination/economics/methods en_US
dc.subject Viral Vaccines/administration & dosage/economics/immunology en_US
dc.title Cost-effectiveness of norovirus vaccination in children in Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/j.vaccine.2015.05.004
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.03
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.05
dc.relation.issn 1873-2518


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas